Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
| ▸ | TCF4 | P15884 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17252023 | 0.93 | TACR1 (0.48) | TACR1ST14HDAC4HDAC3HDAC1 | |
| SCHEMBL17252074 | 0.92 | TACR1 (0.51) | TACR1ST14HDAC4 | |
| Dianthin E SCHEMBL29404462 | 0.83 | ST14 (0.53) | TACR1ST14HDAC4HDAC3HDAC1 | |
| SCHEMBL29352662 | 0.82 | HDAC8 (0.49) | HDAC4HDAC1HDAC8HDAC6 | |
| SCHEMBL28240936 | 0.79 | GHSR (0.52) | ST14HDAC4 | |
| SCHEMBL29779778 | 0.79 | GHSR (0.52) | ST14HDAC4 | |
| SCHEMBL29779774 | 0.79 | ST14 (0.49) | TACR1ST14 | |
| SCHEMBL29220474 | 0.79 | ABCB1 (0.55) | HDAC4OXTR | |
| Antamanide SCHEMBL585268 | 0.78 | HDAC4 (0.60) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL32676347 | 0.78 | PSMB11 (0.53) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150322474-A1 | IN VITRO PRODUCTION OF CYCLIC PEPTIDES | The University of the University of Aberdeen (GB) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322474-A1 | IN VITRO PRODUCTION OF CYCLIC PEPTIDES | NRDC, TRHDE, PTMA | TACR1 3131/4885ST14 378/4885HDAC4 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.